Working… Menu

Response of Clostridium Difficile Infection to Metronidazole Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00304369
Recruitment Status : Completed
First Posted : March 17, 2006
Last Update Posted : February 18, 2013
Baylor College of Medicine
Information provided by (Responsible Party):
Daniel M. Musher MD, VA Medical Center, Houston

Brief Summary:
In this record review study, our objective is to determine the rates of cure, failure and relapse following treatment of C. difficile colitis with metronidazole.

Condition or disease Intervention/treatment
Clostridium Enterocolitis Pseudomembranous Colitis Antibiotic-Associated Colitis Drug: Metronidazole

Detailed Description:

Clostridium difficile is a major cause of nosocomial infection. When this organism proliferates in the colon, usually as a result of prior antibiotic therapy in a hospitalized or otherwise debilitated person, a variety of potentially serious consequences follow, such as fever, leukocytosis, abdominal pain, diarrhea and ileus. Some patients require surgical exploration and colectomy, and our hospital has had several deaths attributable to C. difficile colitis in the past year.

C. difficile colitis is treated with metronidazole, and earlier literature on this subject, written in the 1980's and early 1990s, suggests that the response rate is excellent, exceeding 90-95%. Our clinical observation has suggested that treatment with metronidazole is followed by a surprisingly high rate of failure, perhaps 25-30%. The clinical problem is that there are, at present, no desirable alternatives. Vancomycin, given orally, is said to be highly effective in treating this infection, but this may not be true, and the administration of this drug is associated with emergence of vancomycin-resistant bacteria, a major problem in modern hospitals. No other drug is approved for treatment of C. difficile infection.

We believe it is important to determine the actual rate of failure of treatment with metronidazole. This will provide an impetus for developing new therapeutic approaches.

We will review the records of patients who have been treated for confirmed C. difficile infection with metronidazole at the VAMC for the past 12 months in order to determine the rates of cure, failure, and relapse following therapy. This is a simple record review study to determine if our clinical suspicion is correct, namely, if the rate of failure of metronidazole therapy is much higher than that reported in the medical literature of 10-15 years ago.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 290 participants
Official Title: The Response of Clostridium Difficile Infection to Metronidazole Therapy
Study Start Date : June 2005
Actual Primary Completion Date : June 2007
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • records of patients who have a fecal sample positive for C. difficile toxin and who are then treated for C. difficile colitis with oral metronidazole will be included in this study.

Exclusion Criteria:

  • Patients who did not receive at least 7 days of metronidazole

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00304369

Layout table for location information
United States, Texas
Michael E. Debakey VA Medical Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
VA Medical Center, Houston
Baylor College of Medicine
Layout table for investigator information
Principal Investigator: Daniel M Musher, M.D. VA Medical Center, Houston

Layout table for additonal information
Responsible Party: Daniel M. Musher MD, Principle Investigator, VA Medical Center, Houston Identifier: NCT00304369     History of Changes
Other Study ID Numbers: H-16175
First Posted: March 17, 2006    Key Record Dates
Last Update Posted: February 18, 2013
Last Verified: February 2013
Keywords provided by Daniel M. Musher MD, VA Medical Center, Houston:
Clostridium difficile
Additional relevant MeSH terms:
Layout table for MeSH terms
Enterocolitis, Pseudomembranous
Anti-Infective Agents
Clostridium Infections
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Gram-Positive Bacterial Infections
Bacterial Infections
Anti-Bacterial Agents
Antiprotozoal Agents
Antiparasitic Agents